Van ECK Associates Corp Acquires 29,297 Shares of United Therapeutics Corporation $UTHR

Van ECK Associates Corp raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 282.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 39,660 shares of the biotechnology company’s stock after acquiring an additional 29,297 shares during the period. Van ECK Associates Corp’s holdings in United Therapeutics were worth $16,626,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Abich Financial Wealth Management LLC purchased a new position in shares of United Therapeutics during the third quarter valued at approximately $44,000. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, True Wealth Design LLC boosted its holdings in United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Ray Kurzweil sold 4,910 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.02, for a total value of $2,401,088.20. Following the completion of the sale, the director owned 12,670 shares in the company, valued at $6,195,883.40. This represents a 27.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total value of $5,125,630.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $70,140.20. This trade represents a 98.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 338,947 shares of company stock valued at $165,516,573 in the last ninety days. 10.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on UTHR. TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada raised their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. HC Wainwright lifted their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company increased their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $548.09.

United Therapeutics Stock Up 0.4%

UTHR traded up $2.28 during trading on Friday, hitting $535.10. The company’s stock had a trading volume of 59,981 shares, compared to its average volume of 423,773. The business’s 50 day simple moving average is $485.89 and its 200-day simple moving average is $458.53. The firm has a market cap of $23.45 billion, a PE ratio of 19.21, a P/E/G ratio of 1.96 and a beta of 0.84. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $548.12.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.19 EPS. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.